AI infrastructure startup Mercor has raised $350 million in Series C funding, quintupling its valuation to $10 billion, the company confirmed to TechCrunch.
AI infrastructure startup Mercor has raised $350 million in Series C funding, quintupling its valuation to $10 billion, the company confirmed to TechCrunch.
Emerging biotech Adaptam Therapeutics has raised €3 million in pre-seed funding to advance a new class of cancer immunotherapies that target immunosuppressive myeloid cells, a key driver of resistance in solid tumors.
Swedish biotech startup Cellcolabs has secured $12 million in primary funding from Titian Capital’s life sciences platform, bringing its total raised to $37 million.
A new player is emerging in Canada’s digital finance ecosystem. Loon, a FinTech startup spun out of Toronto-based Paytrie, has raised $3 million CAD in pre-seed funding to take over and scale CADC, a Canadian dollar-backed stablecoin first launched by Paytrie in 2021.
DeepTech startup Cytely has raised €3 million to accelerate the rollout of its smart microscopy platform, which transforms standard laboratory microscopes into real-time data analysis engines.
Growth equity firm Iris Ventures has announced the first close of its second fund, IRIS Fund II, raising €100 million toward a €200 million target to back the next generation of purpose-driven consumer and lifestyle brands across beauty, wellness, nutrition, longevity, and conscious living.
Conversational AI startup Aunoa has secured €1.5 million in funding to expand its intelligent automation platform across Europe and strengthen its presence in high-volume customer engagement sectors.
Advanced materials innovator Immaterial has raised €15.4 million in Series A2 funding to accelerate the commercial rollout of its monolithic metal–organic frameworks (m-MOFs) — a breakthrough material platform designed to cut costs and boost efficiency across industrial decarbonisation, carbon capture, and hydrogen storage.
Clinical-stage biotech Elevara Medicines has raised $70 million in Series A financing to advance its novel therapies for rheumatoid arthritis (RA) and other chronic inflammatory diseases — marking one of Europe’s largest early-stage rounds in immunology this year.
